2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr Miller discusses findings from the SIENDO trial of selinexor maintenance therapy in patients with TP53 wild-type advanced endometrial cancer.
Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.
OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by Karyopharm Therapeutics, we had the pleasure of speaking with David Miller, MD, about the long-term follow-up of the subgroup analysis of the phase 3 SIENDO trial (NCT03555422) investigating selinexor maintenance therapy in patients with TP53 wild-type advanced or recurrent endometrial cancer. Dr Miller is a professor and chief of the Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology, as well as the Amy and Vernon R. Faulconer Distinguished Chair in Gynecologic Oncology at the University of Texas (UT) Southwestern Medical School in Dallas. He is also the medical director of the UT Southwestern Harold C. Simmons Cancer Center.
In our exclusive interview, Dr Miller discussed unmet needs in the endometrial cancer treatment paradigm that led to the initiation of SIENDO, key updated efficacy findings from the subgroup analysis in patients with TP53 wild-type disease, and what the future for selinexor development may look like in this patient population.
___
That’s all we have for today! Thank you for listening to this episode of OncLive On Air, sponsored by Karyopharm Therapeutics. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air.
*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.